REFERENCES
1. Mahmoud R, Kimonis V, Butler MG. Genetics of obesity in humans: a clinical review. Int J Mol Sci. 2022;23:11005.
2. Chami N, Wang Z, Svenstrup V, et al. Genetic subtyping of obesity reveals biological insights into the uncoupling of adiposity from its cardiometabolic comorbidities. Nat Med. 2025;31:3801-12.
3. Farooqi IS. Genetic and hereditary aspects of childhood obesity. Best Pract Res Clin Endocrinol Metab. 2005;19:359-74.
4. Singh RK, Kumar P, Mahalingam K. Molecular genetics of human obesity: a comprehensive review. C R Biol. 2017;340:87-108.
5. Duis J, Butler MG. Syndromic and nonsyndromic obesity: underlying genetic causes in humans. Adv Biol. 2022;6:e2101154.
6. Andermann ML, Lowell BB. Toward a wiring diagram understanding of appetite control. Neuron. 2017;95:757-78.
9. Balthasar N, Dalgaard LT, Lee CE, et al. Divergence of melanocortin pathways in the control of food intake and energy expenditure. Cell. 2005;123:493-505.
10. Wu Q, Palmiter RD. GABAergic signaling by AgRP neurons prevents anorexia via a melanocortin-independent mechanism. Eur J Pharmacol. 2011;660:21-7.
11. Tong Q, Ye CP, Jones JE, Elmquist JK, Lowell BB. Synaptic release of GABA by AgRP neurons is required for normal regulation of energy balance. Nat Neurosci. 2008;11:998-1000.
12. Huvenne H, Dubern B, Clément K, Poitou C. Rare genetic forms of obesity: clinical approach and current treatments in 2016. Obes Facts. 2016;9:158-73.
13. Mohammed I, Ahmed WS, Al-Barazenji T, Dauleh H, Love DR, Hussain K. Novel SIM1 variants expanding the spectrum of SIM1-related obesity. Int J Mol Sci. 2026;27:533.
14. Dietrich J, Lovell S, Veatch OJ, Butler MG. PHIP gene variants with protein modeling, interactions, and clinical phenotypes. Am J Med Genet A. 2022;188:579-89.
15. Li Y, Kim MH, Jiang L, et al. SH2B1 defends against energy imbalance, obesity, and metabolic disease via a paraventricular hypothalamus→dorsal raphe nucleus neurocircuit. Adv Sci. 2024;11:e2400437.
16. Polex-Wolf J, Yeo GS, O’Rahilly S. Impaired prohormone processing: a grand unified theory for features of Prader-Willi syndrome? J Clin Invest 2017;127:98-9.
17. Van Dijck E, Beckers S, Diels S, et al. Rare heterozygous PCSK1 variants in human obesity: the contribution of the p.Y181H variant and a literature review. Genes. 2022;13:1746.
18. Qian Y, Wu B, Liu R, et al. Case report: complete maternal uniparental isodisomy of chromosome 5 (iUPD(5)mat) with PCSK1 nonsense variant in an infant with recurrent diarrhea. Front Genet. 2021;12:668326.
19. Tao YX. The melanocortin-4 receptor: physiology, pharmacology, and pathophysiology. Endocr Rev. 2010;31:506-43.
20. Loos RJF, Yeo GSH. The genetics of obesity: from discovery to biology. Nat Rev Genet. 2022;23:120-33.
21. Kleinendorst L, Massink MPG, Cooiman MI, et al. Genetic obesity: next-generation sequencing results of 1230 patients with obesity. J Med Genet. 2018;55:578-86.
22. Künzel R, Faust H, Bundalian L, et al. Detecting monogenic obesity: a systematic exome-wide workup of over 500 individuals. Int J Obes. 2025;49:1400-11.
24. Chami N, Preuss M, Walker RW, Moscati A, Loos RJF. The role of polygenic susceptibility to obesity among carriers of pathogenic mutations in MC4R in the UK Biobank population. PLoS Med. 2020;17:e1003196.
25. Hinney A, Schmidt A, Nottebom K, et al. Several mutations in the melanocortin-4 receptor gene including a nonsense and a frameshift mutation associated with dominantly inherited obesity in humans. J Clin Endocrinol Metab. 1999;84:1483-6.
26. Biebermann H, Krude H, Elsner A, Chubanov V, Gudermann T, Grüters A. Autosomal-dominant mode of inheritance of a melanocortin-4 receptor mutation in a patient with severe early-onset obesity is due to a dominant-negative effect caused by receptor dimerization. Diabetes. 2003;52:2984-8.
27. Stutzmann F, Tan K, Vatin V, et al. Prevalence of melanocortin-4 receptor deficiency in Europeans and their age-dependent penetrance in multigenerational pedigrees. Diabetes. 2008;57:2511-8.
28. Farooqi IS, Yeo GS, Keogh JM, et al. Dominant and recessive inheritance of morbid obesity associated with melanocortin 4 receptor deficiency. J Clin Invest. 2000;106:271-9.
29. Hinney A, Volckmar AL, Knoll N. Melanocortin-4 receptor in energy homeostasis and obesity pathogenesis. Prog Mol Biol Transl Sci. 2013;114:147-91.
30. Zorn S, Bounds R, Williamson A, et al. Obesity due to MC4R deficiency is associated with reduced cholesterol, triglycerides and cardiovascular disease risk. Nat Med. 2025;31:4180-8.
31. Marx N, Husain M, Lehrke M, Verma S, Sattar N. GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes. Circulation. 2022;146:1882-94.
33. Kühnen P, Krude H, Biebermann H. Melanocortin-4 receptor signalling: importance for weight regulation and obesity treatment. Trends Mol Med. 2019;25:136-48.
34. Farooqi IS, Keogh JM, Yeo GS, Lank EJ, Cheetham T, O’Rahilly S. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N Engl J Med. 2003;348:1085-95.
35. Vaisse C, Clement K, Durand E, Hercberg S, Guy-Grand B, Froguel P. Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity. J Clin Invest. 2000;106:253-62.
36. Fan W, Dinulescu DM, Butler AA, Zhou J, Marks DL, Cone RD. The central melanocortin system can directly regulate serum insulin levels. Endocrinology. 2000;141:3072-9.
37. Hui H, Yu Y, Yiwei L, Li Y, Liling X, Dongguang Z. Genetic etiology and clinical features of non-syndromic pediatric obesity in the Chinese population: a large cohort study. BMC Pediatr. 2025;25:358.
38. Trier C, Hollensted M, Schnurr TM, et al. Obesity treatment effect in Danish children and adolescents carrying Melanocortin-4 Receptor mutations. Int J Obes. 2021;45:66-76.
39. Gong Y, Wu Q, Huang S, et al. Functional characterization of MC4R variants in Chinese morbid obese patients and weight loss after bariatric surgery. Adv Biol. 2023;7:e2300007.
40. Reinehr T, Hebebrand J, Friedel S, et al. Lifestyle intervention in obese children with variations in the melanocortin 4 receptor gene. Obesity. 2009;17:382-9.
41. Hainerová I, Larsen LH, Holst B, et al. Melanocortin 4 receptor mutations in obese Czech children: studies of prevalence, phenotype development, weight reduction response, and functional analysis. J Clin Endocrinol Metab. 2007;92:3689-96.
42. Zhu H, Yi X, He M, Wu S, Li M, Gao S. Exploring the interplay of genetic variants and environmental factors in childhood obesity: a systematic review and meta-analysis. Metabolism. 2025;170:156303.
43. Cooiman MI, Alsters SIM, Duquesnoy M, et al. Long-term weight outcome after bariatric surgery in patients with melanocortin-4 receptor gene variants: a case-control study of 105 patients. Obes Surg. 2022;32:837-44.
44. Fojas EGF, Radha SK, Ali T, Nadler EP, Lessan N. Weight and glycemic control outcomes of bariatric surgery and pharmacotherapy in patients with melanocortin-4 receptor deficiency. Front Endocrinol. 2021;12:792354.
45. Poitou C, Puder L, Dubern B, et al. Long-term outcomes of bariatric surgery in patients with bi-allelic mutations in the POMC, LEPR, and MC4R genes. Surg Obes Relat Dis. 2021;17:1449-56.
46. Campos A, Cifuentes L, Hashem A, et al. Effects of heterozygous variants in the leptin-melanocortin pathway on Roux-en-Y gastric bypass outcomes: a 15-year case-control study. Obes Surg. 2022;32:2632-40.
47. Zhang N, Wang H, Ran S, et al. Mutations in the leptin-melanocortin pathway and weight loss after bariatric surgery: a systematic review and meta-analysis. Obesity. 2024;32:1047-58.
48. U. S. Food & Drug Administration. FDA approves first treatment for weight management for people with certain rare genetic conditions. Available from: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-treatment-weight-management-people-certain-rare-genetic-conditions. [Last accessed on 8 Jul 2026].
49. European Medicines Agency. Imcivree (setmelanotide): EPAR - product information. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/imcivree. [Last accessed on 8 Jul 2026].
50. Rodríguez Rondón AV, Welling MS, van den Akker ELT, et al. MC4R variants modulate α-MSH and setmelanotide induced cellular signaling at multiple levels. J Clin Endocrinol Metab. 2024;109:2452-66.
51. Phillips SA, van Santen HM, Hamilton JK, et al. OR11-01 efficacy and safety of setmelanotide in acquired hypothalamic obesity: results from a double-blind, multicenter, placebo-controlled, randomized phase 3 trial. J Endocr Soc. 2025;9:bvaf149.074.
52. Clément K, van den Akker E, Argente J, et al. ; Setmelanotide POMC and LEPR Phase 3 Trial Investigators. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. Lancet Diabetes Endocrinol. 2020;8:960-70.
54. Clément K, Mosbah H, Poitou C. Rare genetic forms of obesity: from gene to therapy. Physiol Behav. 2020;227:113134.
55. Collet TH, Dubern B, Mokrosinski J, et al. Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency. Mol Metab. 2017;6:1321-9.
56. Kühnen P, Clément K, Wiegand S, et al. Proopiomelanocortin deficiency treated with a melanocortin-4 receptor agonist. N Engl J Med. 2016;375:240-6.
57. Finimize. Rhythm Pharma’s Rare-Obesity drug keeps growth rolling. Available from: https://finimize.com/content/rytm-asset-snapshot. [Last accessed on 8 Jul 2026].
58. European Clinical Trials Database (EudraCT). Setmelanotide (RM-493) phase 2 treatment trial in patients with rare genetic disorders of obesity. Results for EudraCT number: 2017-000387-14. Available from: https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000387-14/results. [Last accessed on 8 Jul 2026].
59. AInvest. Rhythm pharmaceuticals’ $150M offering: fueling rare disease innovation amid dilution risks. Available from: https://www.ainvest.com/news/rhythm-pharmaceuticals-150m-offering-fueling-rare-disease-innovation-dilution-risks-2507/. [Last accessed on 8 Jul 2026].
60. Nauck MA, Wollschläger D, Werner J, et al. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia. 1996;39:1546-53.
61. Kim KS, Park JS, Hwang E, et al. GLP-1 increases preingestive satiation via hypothalamic circuits in mice and humans. Science. 2024;385:438-46.
62. Secher A, Jelsing J, Baquero AF, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest. 2014;124:4473-88.
63. Dong Y, Carty J, Goldstein N, He Z, Hwang E, Chau D. Time and metabolic state-dependent effects of GLP-1R agonists on NPY/AgRP and POMC neuronal activity in vivo. Mol Metab. 2021;54:101352.
64. Velji-Ibrahim J, Radadiya D, Devani K, et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists for obesity management in adults with and without type 2 diabetes: a systematic review. J Obes. 2025;2025:3897161.
65. Xie Z, Zheng G, Liang Z, Li M, Deng W, Cao W. Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials. Metabolism. 2024;161:156038.
66. Eckert P, Nöller M, Müller M, et al. Targeting GLP-1 signaling ameliorates cystogenesis in a zebrafish model of nephronophthisis. Int J Mol Sci. 2025;26:7366.
67. Iepsen EW, Zhang J, Thomsen HS, et al. Patients with obesity caused by melanocortin-4 receptor mutations can be treated with a glucagon-like peptide-1 receptor agonist. Cell Metab. 2018;28:23-32.e3.
68. Iepsen EW, Have CT, Veedfald S, et al. GLP-1 receptor agonist treatment in morbid obesity and type 2 diabetes due to pathogenic homozygous melanocortin-4 receptor mutation: a case report. Cell Rep Med. 2020;1:100006.
69. Zaitoon H, Lubetzky R, Amir AZ, et al. Glucagon-like peptide-1 analog therapy in rare genetic diseases: monogenic obesity, monogenic diabetes, and spinal muscular atrophy. Acta Diabetol. 2023;60:1099-108.
70. Iepsen EW, Zhang J, Hollensted M, et al. Adults with pathogenic MC4R mutations have increased final height and thereby increased bone mass. J Bone Miner Metab. 2020;38:117-25.
71. Li X, Li Y, Lei C. Effects of glucagon-like peptide-1 receptor agonists on bone metabolism in type 2 diabetes mellitus: a systematic review and meta-analysis. Int J Endocrinol. 2024;2024:1785321.
72. Cosman F, de Beur SJ, LeBoff MS, et al. ; National Osteoporosis Foundation. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25:2359-81.
73. O’Neil PM, Birkenfeld AL, McGowan B, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018;392:637-49.
74. Ahmann AJ, Capehorn M, Charpentier G, et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. Diabetes Care. 2018;41:258-66.
75. Pratley RE, Aroda VR, Lingvay I, et al. ; SUSTAIN 7 investigators. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6:275-86.
76. Gokul PR, Apperley L, Parkinson J, et al. Semaglutide, a long-acting GLP-1 analogue, for the management of early-onset obesity due to MC4R defect: a case report. Horm Res Paediatr. 2025;98:148-55.
77. Gad H, Mohammed I, Dauleh H, et al. Case report: nerve fiber regeneration in children with melanocortin 4 receptor gene mutation related obesity treated with semaglutide. Front Endocrinol. 2024;15:1385463.
78. Phan A, Carette C, Narjoz C, et al. A GLP1R gene variant and sex influence the response to semaglutide treatment in patients with severe obesity. Obesity. 2025;33:1237-42.
79. Li G, Hu Y, Zhang W, et al. FTO variant is associated with changes in BMI, ghrelin, and brain function following bariatric surgery. JCI Insight. 2024;9:e175967.
80. Aronne LJ, Horn DB, le Roux CW, et al. ; SURMOUNT-5 Trial Investigators. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025;393:26-36.
81. Hansford R, Buller S, Tsang AH, et al. Glucose-dependent insulinotropic polypeptide receptor signaling in oligodendrocytes increases the weight-loss action of GLP-1R agonism. Cell Metab. 2025;37:1820-34.e5.
82. Jiang Y, Zhu H, Gong F. Why does GLP-1 agonist combined with GIP and/or GCG agonist have greater weight loss effect than GLP-1 agonist alone in obese adults without type 2 diabetes? Diabetes Obes Metab 2025;27:1079-95.
83. James-Okoro PP, Lewis JE, Gribble FM, Reimann F. The role of GIPR in food intake control. Front Endocrinol. 2025;16:1532076.
84. Liu J, Jing C, Guo Y, et al. The central signaling pathways related to metabolism-regulating hormones of the gut-brain axis: a review. J Transl Med. 2025;23:648.
85. Elmendorf AJ, Yousefian M, Kim IM, Hardaway JA, Habegger K, Flak JN. IUPHAR review: from foe to friend: Repurposing glucagon to treat obesity and type 2 diabetes. Pharmacol Res. 2026;223:108077.
86. Liu QK. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists. Front Endocrinol. 2024;15:1431292.
